Osmotica Pharmaceuticals

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases. At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10% owners really only buy shares of a company...

Drug developer Osmotica Pharmaceuticals is expected to begin trading Thursday on the Nasdaq Global Market under the ticker symbol “OSMT.” The Details Over 60 percent of Osmotica's total revenues in 2017 and 80 percent of the first half of 2018 were produced by the sales of generic...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. Allogene Therapeutics, Inc. (ALLO) will issue 16 million shares between $16 and $18 Thursday on the Nasdaq. With a portfolio acquired from Pfizer Inc. (NYSE: PFE), the biotech firm develops allogeneic CAR-T therapies...